TAP Consulting’s Bolt Biotherapeutics BOLT Stock Holding History

TAP Consulting’s Portfolio BOLT Stock Details BOLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1	Closed	–	–	186
2021 Q4	$0	Buy	+1	New	+$190	﹤0.01%	563

Other funds holding BOLT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

ESCM

Echo Street Capital Management New York $747M AUM 24.25% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

TAP Consulting's BOLT Position: Q1 2022 in Review

TAP Consulting sold out of Bolt Biotherapeutics (BOLT) in Q1 2022, closing a stake of 1 share.

TAP Consulting first reported a position in BOLT in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 65 funds tracked by Wall St. Rank hold BOLT as of Q1 2022.

TAP Consulting reported no remaining Bolt Biotherapeutics position as of Q1 2022 after selling out during the quarter.
TAP Consulting sold 1 Bolt Biotherapeutics share in Q1 2022.
TAP Consulting first reported a position in Bolt Biotherapeutics in Q4 2021 and held it in 1 quarter.
TAP Consulting's Bolt Biotherapeutics position peaked at $0 in Q4 2021.
65 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2022.

Based on TAP Consulting's 13F filing for Q1 2022, filed 26 Apr 2022.